WO1986000912A1 - Gel for preventing adhesion between body tissues and process for its production - Google Patents
Gel for preventing adhesion between body tissues and process for its production Download PDFInfo
- Publication number
- WO1986000912A1 WO1986000912A1 PCT/SE1985/000282 SE8500282W WO8600912A1 WO 1986000912 A1 WO1986000912 A1 WO 1986000912A1 SE 8500282 W SE8500282 W SE 8500282W WO 8600912 A1 WO8600912 A1 WO 8600912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- acid
- acids
- polysaccharide
- carboxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Definitions
- This invention is concerned with a method of preventing adhesions or accretions of body tissues inter se with the aid of a degradable gel of a crosslinked polysaccharide containing carboxyl groups.
- the invention also comprises a gel product which is suited to this purpose, and a process for producing that gel product.
- Tubular implants may be employed for obtaining an improved flow from the anterior chamber, for thwarting obstruction of the lachrymal duct, and for improving the result of dacryo- cystorhinostom .
- the present invention is thus concerned with a novel degra ⁇ dable gel consisting of a polysaccharide which contains carboxyl groups - such as for example carboxymethyl starch, carboxymethyl dextran, carboxymethyl cellulose and glucos- aminoglycans such as e.g. heparin, heparan sulfate, chon- Georgiain sulfate and hyaluronic acid - and which has been crosslinked with a di- or polyfunctional epoxide.
- carboxyl groups - such as for example carboxymethyl starch, carboxymethyl dextran, carboxymethyl cellulose and glucos- aminoglycans such as e.g. heparin, heparan sulfate, chon- Georgiain sulfate and hyaluronic acid - and which has been crosslinked with a di- or polyfunctional epoxide.
- epoxides examples include 1,4-butanediol diglycidyl ether (BDDE) , 1,2-ethanediol diglycidyl ether (EDDE) , 1- (2,3-epoxypropyl) - 2, 3-epoxycyclohexane (Bakelite epoxy resin ERL 4206, Union Carbide) , N,N-diglycidyl aniline (Leuktherm X 50, Bayer) , and epoxy-substituted pentaerythritol (Shell 162) .
- BDDE 1,4-butanediol diglycidyl ether
- EDDE 1,2-ethanediol diglycidyl ether
- 1- (2,3-epoxypropyl) - 2, 3-epoxycyclohexane Bakelite epoxy resin ERL 4206, Union Carbide
- N,N-diglycidyl aniline Leuktherm X 50, Bayer
- the crosslinking has been carried out in an acidic medium, in the presence of an acidic catalyst.
- a great number of substances have been found to act as catalysts in the crosslinking reaction. Examples of such substances are inorganic acids such as e.g. sulfuric acid, nitric acid, hydrochloric acid and phosphoric acid; furthermore organic mono- and polycarboxylic acids, e.g.
- lower aliphatic acids such as for instance formic acid, acetic acid, propionic acid, lactic acid, trichloroacetic acid, succinic acid, and aromatic mono- or polyfunctional carboxylic acids or sulfonic acids, e.g. benzoic, salicylic and paratoluenesulfonic acids.
- polycarboxylic acids comprises all acids having more than one carboxyl group. It is possible to replace the free acids employed by their hydrogen salts in those cases where such salts can be formed.
- the present invention also relates to a process for producing a degradable gel by means of reacting a carboxyl-containing polysaccharide with a bi- or polyfunctional epoxide at a pH of from 2 to 5, preferably from 2.5 to 4.5, in the presence of an acidic catalyst of the aforesaid type.
- the carboxyl- containing polysaccharide is hyaluronic acid or a salt thereof such as the sodium salt.
- Hyaluronic acid exists in a wide range of forms of different molecular weights depending on its source and on the purification methods employed. Products within the range of 20,000 to 5,000,000, in particular 500,000 to 3,000,000, are suitable for producing gels according to this invention.
- the concentrations of such hya ⁇ luronic acids in the reaction mixture may suitably be 5 to 10 % by weight. Considerably higher concentrations have to be employed for achieving gel formation with low molecular polysaccharide starting materials.
- the amount of crosslinking agent may be varied within a very broad range, from about 10 to about 500 % by weight of the hyaluronic acid, depending on the particular properties desired in the gel.
- the reaction may advantageously be performed at an elevated temperature of 30 to 80 C, although temperatures of 30 - 50 C are preferred for minimizing the risk of acid hydrolysis. As regards the reaction time, this is usually chosen within the range of from 3 to 20 hours, a preferred range being 5 to 15 hours.
- the dry solids content of a gel swelled in physiological saline will preferably be within the range of from 0.5 to 10 % by weight.
- novel gels of this invention are degradable; a hya- luronate gel implanted in a rat was found to undergo slow swelling while, at the same time gradually loosing its shape and rigidity. After 32 hours the gel had lost its integrity (intactness) . Such gels therefore are suitable to be used in cases where the contact-inhibiting effect is to be upheld for several days.
- the gel to be chosen will e.g. be one according to the present invention having a high degree of crosslinking or will be an alkali-catalyzed gel of the type described in the Swedish patent application No. 8403090-7.
- Crosslinked hyaluronic acid gels of these types especially those according to said Swedish patent application, will degrade quite slowly; their contact-inhibiting effect may therefore persist for several months.
- said Swedish patent application describes the use of certain alkali-catalyzed gels as vitreous humor substitutes, this is not comprised by the present invention.
- the gels may be prepared in many different forms depending on the particular use to which they are to be put.
- the reaction mixture is transferred to a suitable container in which the polymerized product will be given its desired form, e.g. thin layers, rods, tubes.
- the gel may be crushed if desired; this will result in a product suitable to be injected into the space or cavity to be filled out by the gel.
- the gel may be sterilized and autoclaved.
- one or more pieces of the gel are introduced, during the course of the surgical operation, into the interstice between the tissues to be maintained in a separated condition.
- the gel that is thus introduced may be partially swollen in a physiologically acceptable solution.
- the swollen gel may be injected in a crushed form into the site where the adhesion-inhibiting effect is desired.
- Example 1 (b) The process of Example 1 (a) was repeated but with 200 ,ul of BDDE and 200 ,ul of glacial acetic acid, and with a reaction time and temperature of 5 hours and 50 C respectively.
- the gel had a solids content of 5.0 %.
- Example 1 (c) The process of Example 1 (a) was repeated but with 600 mg of sodium hyaluronate, 400 ,ul of BDDE and 200 ,ul of glacial acetic acid. The gel had a solids content of 8.4 %.
- Example 1 (d) The process of Example 1 (a) was repeated but with
- the resultant gel had a solids content of 1.6 %.
- Example 1 (e) The procedure of Example 1 (a) was also repeated with the following catalysts: 400 ,ul of 2N sulfuric acid, 200 ,ul of 50 % trichloroacetic acid and, respectively, 200 ,ul of a solution of 1.5 g of benzoic acid in 1.5 ml water and 1.5 ml dimethyl sulfoxide.
- Example 1 (h) The procedure of Example 1 (a) was repeated, but with 200 mg of sodium hyaluronate of molecular weight about 500,000, 250 ,ul BDDE and 100 ,ul glacial acetic acid. The reaction was allowed to proceed overnight at 50 C. This experiment resulted in the formation of a crosslinked hyaluronic acid gel, and the same applies to another run where 200 mg of hyaluronic acid (free acid form) having a molecular weight of about 3 x g 10 was reacted with 200 ,ul of BDDE in the presence of 100 ,ul glacial acetic acid.
- a gel produced in the same manner as in Example 1 was shredded into small pieces. These were weighed and inserted into small Plexiglas chambers which were then covered with nylon net and implanted subcutaneously in rats. After suitable periods of time the gel pieces were removed, weighed and analyzed with respect to their hyaluronate contents, with the results as set forth below.
- the hyaluronate content was determined in accordance with three mutually independent methods: The orcinol method (Mejbaum W. , Physiol. Chem. 258 (1939) , 117) , the hyaluronidase method (Dische Z., J. Biol. Chem. 167 (1947) , 189) , and the carbazole method (Jourdian G.W.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of preventing adhesions or accretions of body tissues inter se by means of employing a degradable gel of a crosslinked carboxyl-containing polysaccharide. The invention also covers a gel product to be used for this purpose, and a process for preparing said product by means of crosslinking with a di- or polyfunctional epoxide at a pH of from 2 to 5.
Description
Gel for preventing adhesion between body tissues and process for its production.
This invention is concerned with a method of preventing adhesions or accretions of body tissues inter se with the aid of a degradable gel of a crosslinked polysaccharide containing carboxyl groups. The invention also comprises a gel product which is suited to this purpose, and a process for producing that gel product.
In many instances of practical surgery, it is highly desir¬ able to have a simple means and method for preventing direct contact between tissues and for maintaining this contact- inhibiting effect also during a postoperative period the length of which will vary according to the actual type of surgery involved. Examples of such surgical procedures are manifold, spanning over a wide field: E.g. operations performed in abdominal regions where it is important to prevent adhesion's of the intestine or the mesentery with concomitant gastrointestinal disorders; operations performed in the urogenital apparatus where it is important to ward off adverse effects on the ureter and bladder, and on the functioning of the oviduct and uterus; and nerve surgery operations where it is important to minimize the development of granulation tissue. When tendons are operated on there is generally a tendency towards adhesion between the tendon and the surrounding sheath or other surrounding tissue during the immobilization period following the operation. Essentially unsuccessful attempts have been made to solve this problem by using various kinds of sutures and by means of passive movements of the tendon during the healing process. In ophthalmological surgery it is often desirable to have degradable implants at one's disposal which are to be applied in the angle of the anterior chamber of the eye for the purpose of preventing synechiae between the cornea and the iris; this applies especially in cases of reconstructions after severe damaging events. Moreover degradable or permanent
implants are often desirable means for preventing adhesion in e.g. glaucoma surgery contexts (preventing adhesion in the subconjunσtival filtration space) and in strabismus surgery.
Tubular implants may be employed for obtaining an improved flow from the anterior chamber, for thwarting obstruction of the lachrymal duct, and for improving the result of dacryo- cystorhinostom .
In one particular type of articular surgery described by Engkvist et al. in Scand. J. Plast. Reconstr. Surg. 14 (1980) , 71-87, silicone plates Silastic 1/2 (Dow Corning) are introduced surgically in order to prevent accretions of cartilaginous tissue. After some 12 to 16 weeks, however, it is necessary to again remove the implant surgically. Thus, the techniques presently available necessitate removal of the inserted material after a suitable period of time in all cases where this material has to be of a rigid type for the sake of securing a high degree of mechanical stability. In other cases, where mechanical stability is not a major factor, it has been customary to use non-crosslinked de tran or hyaluronic acid. But even if a substance of such high viscosity as hyaluronic acid is used for application to contact surfaces the protection period thus obtained is too short to be satisfactory.
What is needed is therefore a product which is applicable in a suitable form for preventing adhesions and accretions between tissues and which optionally is to have the property of being degradable after a desired period of time.
We have now found that a gel of a crosslinked carboxyl- containing polysaccharide is exceedingly suitable for being used as a degradable implant.
The present invention is thus concerned with a novel degra¬ dable gel consisting of a polysaccharide which contains
carboxyl groups - such as for example carboxymethyl starch, carboxymethyl dextran, carboxymethyl cellulose and glucos- aminoglycans such as e.g. heparin, heparan sulfate, chon- droitin sulfate and hyaluronic acid - and which has been crosslinked with a di- or polyfunctional epoxide. Examples of such epoxides are 1,4-butanediol diglycidyl ether (BDDE) , 1,2-ethanediol diglycidyl ether (EDDE) , 1- (2,3-epoxypropyl) - 2, 3-epoxycyclohexane (Bakelite epoxy resin ERL 4206, Union Carbide) , N,N-diglycidyl aniline (Leuktherm X 50, Bayer) , and epoxy-substituted pentaerythritol (Shell 162) . These crosslinking reagents and other suitable epoxy compounds are well known to persons skilled in the art. The same applies to the choice of polysaccharides available which either contain carboxyl groups from the outset or may be derivatized so as to then contain such groups. The crosslinking has been carried out in an acidic medium, in the presence of an acidic catalyst. A great number of substances have been found to act as catalysts in the crosslinking reaction. Examples of such substances are inorganic acids such as e.g. sulfuric acid, nitric acid, hydrochloric acid and phosphoric acid; furthermore organic mono- and polycarboxylic acids, e.g. lower aliphatic acids such as for instance formic acid, acetic acid, propionic acid, lactic acid, trichloroacetic acid, succinic acid, and aromatic mono- or polyfunctional carboxylic acids or sulfonic acids, e.g. benzoic, salicylic and paratoluenesulfonic acids. The term "polycarboxylic acids" comprises all acids having more than one carboxyl group. It is possible to replace the free acids employed by their hydrogen salts in those cases where such salts can be formed.
The present invention also relates to a process for producing a degradable gel by means of reacting a carboxyl-containing polysaccharide with a bi- or polyfunctional epoxide at a pH of from 2 to 5, preferably from 2.5 to 4.5, in the presence of an acidic catalyst of the aforesaid type.
In a preferred embodiment of the invention the carboxyl- containing polysaccharide is hyaluronic acid or a salt thereof such as the sodium salt. Hyaluronic acid exists in a wide range of forms of different molecular weights depending on its source and on the purification methods employed. Products within the range of 20,000 to 5,000,000, in particular 500,000 to 3,000,000, are suitable for producing gels according to this invention. In cases where the mole- cular weight exceeds 10 the concentrations of such hya¬ luronic acids in the reaction mixture may suitably be 5 to 10 % by weight. Considerably higher concentrations have to be employed for achieving gel formation with low molecular polysaccharide starting materials. Similarly, the amount of crosslinking agent may be varied within a very broad range, from about 10 to about 500 % by weight of the hyaluronic acid, depending on the particular properties desired in the gel. The reaction may advantageously be performed at an elevated temperature of 30 to 80 C, although temperatures of 30 - 50 C are preferred for minimizing the risk of acid hydrolysis. As regards the reaction time, this is usually chosen within the range of from 3 to 20 hours, a preferred range being 5 to 15 hours.
The dry solids content of a gel swelled in physiological saline will preferably be within the range of from 0.5 to 10 % by weight.
IR analysis of a gel produced in a manner analogous to that of Example 1 below showed a significant peak in its IR spectrum at about 1745 cm , which is characteristic of an O-ester group. This peak remained in the spectrum also after the gel had been treated with phosphate buffer (pH 6.8); in that stage most of the carboxyl groups are ionized and thus unable to contribute to the aforesaid peak. These results indicate, thus, that the acid-catalyzed gels do contain O-ester bridges. Gels produced by means of alkaline catalysis (see for instance Laurent et al., Acta Chim. Scand. 18 (1964) 274-275) do not show such a peak at 1745 cm-1.
The novel gels of this invention are degradable; a hya- luronate gel implanted in a rat was found to undergo slow swelling while, at the same time gradually loosing its shape and rigidity. After 32 hours the gel had lost its integrity (intactness) . Such gels therefore are suitable to be used in cases where the contact-inhibiting effect is to be upheld for several days.
If it is desired that the contact-inhibiting effect is maintained during a considerably longer period of time the gel to be chosen will e.g. be one according to the present invention having a high degree of crosslinking or will be an alkali-catalyzed gel of the type described in the Swedish patent application No. 8403090-7. Crosslinked hyaluronic acid gels of these types, especially those according to said Swedish patent application, will degrade quite slowly; their contact-inhibiting effect may therefore persist for several months. In so far as said Swedish patent application describes the use of certain alkali-catalyzed gels as vitreous humor substitutes, this is not comprised by the present invention.
The gels may be prepared in many different forms depending on the particular use to which they are to be put. When the individual components have been added, the reaction mixture is transferred to a suitable container in which the polymerized product will be given its desired form, e.g. thin layers, rods, tubes. After the polymerization step, the gel may be crushed if desired; this will result in a product suitable to be injected into the space or cavity to be filled out by the gel.
It is imperative to have the polysaccharide duly purified •from components that might otherwise cause toxic or undesired im unological reactions. Similarly, it is necessary that the final gel be liberated by careful washing from e.g. unreacted crosslinking reagent. The gel may be sterilized and autoclaved.
To carry out the method of this invention for preventing mutual adhesion or accretion (synechia) of body tissues, one or more pieces of the gel are introduced, during the course of the surgical operation, into the interstice between the tissues to be maintained in a separated condition. The gel that is thus introduced may be partially swollen in a physiologically acceptable solution. Alternatively, the swollen gel may be injected in a crushed form into the site where the adhesion-inhibiting effect is desired.
EXAMPLES
Preparation of gels of crosslinked hyaluronic acid
1 (a) 400 mg of sodium hyaluronate having a molecular weight of about 3 x 10 was dissolved in 4 ml of distilled water in a plastic test tube. After about 2 hours, 600 ,ul of 1, -butanediol di¬ glycidyl ether (BDDE) was added and then, after agitation, 150 ,ul of glacial acetic acid. The mixture was left standing for 15 hours at 60 to 70 C, whereupon the gel thus formed was washed with water. The solids content of the swollen gel was 3.3 % (% by weight of swollen gel in physio¬ logical saline) .
1 (b) The process of Example 1 (a) was repeated but with 200 ,ul of BDDE and 200 ,ul of glacial acetic acid, and with a reaction time and temperature of 5 hours and 50 C respectively. The gel had a solids content of 5.0 %.
1 (c) The process of Example 1 (a) was repeated but with 600 mg of sodium hyaluronate, 400 ,ul of BDDE and 200 ,ul of glacial acetic acid. The gel had a solids content of 8.4 %.
(d) The process of Example 1 (a) was repeated but with
400 mg of sodium hyaluronate having a molecular
- weight of about 1 x 10 and with 150 mg of lactic acid as the catalyst. The resultant gel had a solids content of 1.6 %.
(e) The procedure of Example 1 (a) was also repeated with the following catalysts: 400 ,ul of 2N sulfuric acid, 200 ,ul of 50 % trichloroacetic acid and, respectively, 200 ,ul of a solution of 1.5 g of benzoic acid in 1.5 ml water and 1.5 ml dimethyl sulfoxide.
In all of these cases a gel of crosslinked hya¬ luronate was obtained.
(f) 150 mg of sodium hyaluronate having a molecular
- weight of about 3 x 10 was dissolved in 1.5 ml of water. When the solution was homogeneous 75 ,ul of glacial acetic acid and 75 mg of epoxy-substituted pentaerythritol (Shell 162, degree of substitution about 3.5) were added. The mixture was left standing overnight at 60 C, whereupon the gel thus formed was washed with water. The swollen gel had a solids content of 2.4 %.
(g) The procedure according to Example 1 (a) was repeated, but with 75 -mg of N,N-diglycidyl aniline (Leuktherm X50, Bayer) as the crosslinking reagent and with 400 ,ul of 2N sulfuric acid as the catalyst. The gel had a solids content of 3.7 %.
(h) The procedure of Example 1 (a) was repeated, but with 200 mg of sodium hyaluronate of molecular weight about 500,000, 250 ,ul BDDE and 100 ,ul glacial acetic acid. The reaction was allowed to proceed overnight at 50 C. This experiment resulted in the formation of a crosslinked
hyaluronic acid gel, and the same applies to another run where 200 mg of hyaluronic acid (free acid form) having a molecular weight of about 3 x g 10 was reacted with 200 ,ul of BDDE in the presence of 100 ,ul glacial acetic acid.
1 (i) Experiments were run in a manner analogous to that of Example 1 (a) but employing in one case 300 mg of sodium hyaluronate and 150 ,ul of BDDE in the presence of 150 ,ul of glacial acetic acid and in the other case 300 mg of sodium hyaluronate and 250 ,ul of BDDE in the presence of 250 ,ul of glacial acetic acid. Gels were obtained in which the content of crosslinking agent amounted to 9 and 21 % by weight respectively as measured by GLC.
2. Preparation of gels of crosslinked carboxymethyl dextran, carboxymethyl cellulose, and chondroitin sulfate
2 (a) 600 mg of carboxymethyl dextran having a molecular weight of about 2 x 10 was dissolved in 3 ml of water. Next 300 ,ul of BDDE and 300 ,ul of glacial acetic acid were added, whereupon the mixture was left standing overnight at 50 C. The gel that had formed by then was washed with water.
2 (b) 400 mg of carboxymethyl cellulose (Fluka CMC sodium salt) was dissolved in 3 ml of water, whereafter the reaction was carried out as in Example 2 (a) but with 200 ,ul of BDDE and 200 ,ul of glacial acetic acid. An opalescent elastic gel was obtained.
2 (c) 800 mg of σhondroitin sulfate (sodium salt, Sigma) was dissolved in 2 ml of water, whereafter the reaction was carried out as in Example 2 (a) but with 200 ,ul of BDDE and 100 ,ul of glacial acetic acid. A gel of firm consistency was obtained.
3. Preparation of an alkali-catalyzed gel of crosslinked hyaluronic acid
2.5 g of sodium hyaluronate having a molecular weight of 3 x 10 was dissolved in 18.75 ml of 0.5 % NaOH, with stirring, until a clear homogeneous solution was obtained. 0.94 ml of BDDE was added, and after thorough mixing the solution was introduced into a container in which a gel of desired shape was formed during 2 hours at 50 C. Before being used the gel was washed carefully and sterilized in an autoclave.
This is an example of the more stable type of gels of crosslinked carboxy-containing polysaccharide the preparation of which is described in detail in SE 8403090-7.
4. Degradatio of a hyaluronate gel in vivo (rat)
A gel produced in the same manner as in Example 1 was shredded into small pieces. These were weighed and inserted into small Plexiglas chambers which were then covered with nylon net and implanted subcutaneously in rats. After suitable periods of time the gel pieces were removed, weighed and analyzed with respect to their hyaluronate contents, with the results as set forth below. The hyaluronate content was determined in accordance with three mutually independent methods: The orcinol method (Mejbaum W. , Physiol. Chem. 258 (1939) , 117) , the hyaluronidase method (Dische Z., J. Biol. Chem. 167 (1947) , 189) , and the carbazole method (Jourdian G.W. et al., Anal. Biochem. 96 (1979) , 474) . The results obtained with these three methods were in good agreement inter se, and for this reason only those obtained with the carbazole method are set forth below.
Amount of hyaluronate
Weight before Weight after remaining in Time, implantation, implantation, gel, % of hours mg mg_ original
0 133 100 0 131 100
a) double samples were analyzed b) the samples had taken up water, resulting in a softer jelly consistency
5. Prevention of peritoneal ahesions with hyaluronate gel film
Forty-eight Wistar male rats (250-300 g each) were used. Of these were three animals excluded because they did not survive the operation (one animal in the test group) or died from peritonitis during the first postoperative day (two animals in the control group) .
Anaesthesia was accomplished with a 10 % solution of etorfine and acepromazine (Immobilon , Pharmacia A/S) i.m. and postoperative reversal was achieved with a 10 % solution of diprenorfine (Reuivon , Pharmacia A/S) . Coeliotomy was performed through a 4-cm median incision. One cm to the right of the midline 1x3 cm of peritoneum and underlying muscle was excised. The peritoneal defect was then closed with seven atraumatic 3/0 single silk sutures. At this point of the procedure the animals were randomly allocated to a test group or a control group.
In the test group a hyaluronate gel film prepared according to examples la or 3 with the dimensions 2x2 cm was introduced between the exposed tissue surfaces.
On the seventh day all rats were sacrificed by ether exposure and the abdomen was opened through a left-sided curved incision. The sutured 3 cm long periforeal defect to the right of the midline was visualized and the part of the defect occupied by adhesions was measured in mm. The abdomen was then examined for pathological conditions other than adhesions.
In the test group, that is the hyaluronate gel film treated group, no adhesions were found.
In the control group adhesions involving the greater omentum, and in eight animals the small intestine as well, were present in all animals. The median length of attachment being 27 mm.
No pathological conditions other than adhesions, i.e. bowel obstruction, peritonitis, abscesses or fluid in the abdomen, were found.
6. Prevention of post-operative adhesions between tendon and tendon sheath
Six rabbits were used divided into a test group and a control group with three animals in each. In each animal two tendons in the fore paw were divided and the hyaluronate gel film, prepared according to examples lb or 3, was folded around the tendon after that it had been rejoined with sutures. The tendon sheath was partly sealed. After four weeks, the animals were sacrificed and the operated tendons were inspected.
In the control group, most of the operated tendons presented adhesions to the surrounding tendon sheath. In the test group, however, the adhesions were very rare and of small size.
Claims
A gel of crosslinked carboxyl-containing polysaccharide to be used as an implant for preventing accretions and adhesions of body tissues inter se.
A gel according to claim 1 consisting of a carboxyl- containing polysaccharide crosslinked with a di- or polyfunctional epoxide at a pH within the range of from 2 to 5, preferably from 2.5 to 4.5.
4. A gel according to any of claims 1 to 3 in which said polysaccharide is hyaluronic acid.
*
5. A process for preparing a gel consisting of a cross¬ linked carboxyl-containing polysaccharide formed by reacting the polysaccharide at a pH of from 2 to 5, preferably 2.5 to 4.5, with a bi- or polyfunctional epoxide in the presence of an acid.
6. A process according to claim 5 in which said acid is selected from the group consisting of inorganic acids, organic acids and hydrogen salts thereof.
7. A process according to claim 6 in which said acid is selected from the group consisting of an inorganic acid such as e.g. hydrochloric, sulfuric, nitric or phos¬ phoric acid, and a hydrogen salt of said inorganic acid.
8. A process according to claim 6 in which said acid is selected from among (a) lower aliphatic mono- or polycarboxylic acids such as e.g. formic, acetic, propionic, lactic, trichloroacetic and succinic acids, or (b) aromatic mono- or polycarboxylic acids and sulfonic acids, such as e.g. benzoic, salicylic and p-toluenesulfonic acids, or (c) hydrogen salts of acids belonging to group (a) or (b) .
9. A process according to any of claims 5 to 8 wherein said polysaccharide is hyaluronic acid.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT85903721T ATE47400T1 (en) | 1984-07-23 | 1985-07-16 | GEL FOR THE PREVENTION OF ADHAESION OF BODY TISSUES AND ITS MANUFACTURE. |
JP60503288A JPH0669490B2 (en) | 1984-07-23 | 1985-07-16 | Implant for preventing adhesion between body tissues and method for producing the same |
DE8585903721T DE3573785D1 (en) | 1984-07-23 | 1985-07-16 | Gel for preventing adhesion between body tissues and process for its production |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8403817-3 | 1984-07-23 | ||
SE8403817A SE456346B (en) | 1984-07-23 | 1984-07-23 | GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986000912A1 true WO1986000912A1 (en) | 1986-02-13 |
Family
ID=20356585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1985/000282 WO1986000912A1 (en) | 1984-07-23 | 1985-07-16 | Gel for preventing adhesion between body tissues and process for its production |
Country Status (7)
Country | Link |
---|---|
US (1) | US4886787A (en) |
EP (1) | EP0190215B1 (en) |
JP (1) | JPH0669490B2 (en) |
CA (1) | CA1263647A (en) |
DE (1) | DE3573785D1 (en) |
SE (1) | SE456346B (en) |
WO (1) | WO1986000912A1 (en) |
Cited By (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007898A1 (en) * | 1986-06-18 | 1987-12-30 | Pharmacia Ab | Material of polysaccharides containing carboxyl groups, and a process for producing such polysaccharides |
WO1989002445A1 (en) * | 1987-09-18 | 1989-03-23 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
EP0345370A1 (en) * | 1988-06-08 | 1989-12-13 | Malliner Laboratories Inc. | Use of transparent membranes made of hydrogel polymers as a cover for various organs during surgery |
US4994277A (en) * | 1989-10-31 | 1991-02-19 | Pfizer Hospital Products Group, Inc. | Use of xanthan gum for preventing adhesions |
EP0426368A2 (en) * | 1989-10-31 | 1991-05-08 | Howmedica Inc. | Compositions containing derivatives of chitin for preventing adhesion |
US5017229A (en) * | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US5093319A (en) * | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
EP0507604A2 (en) * | 1991-04-05 | 1992-10-07 | Lifecore Biomedical, Inc. | Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention |
DE4209160A1 (en) * | 1992-03-20 | 1993-09-30 | Bauer Kurt Heinz Prof Dr | Crosslinked polysaccharides, process for their preparation and their use |
EP0686395A2 (en) | 1994-06-07 | 1995-12-13 | Genzyme Corporation | Use of hyaluronic acid for the manufacture of a medicament for the inhibition of platelet aggregation |
EP0610441A4 (en) * | 1991-10-29 | 1996-01-10 | Clover Cons Ltd | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release. |
US5527893A (en) * | 1987-09-18 | 1996-06-18 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
WO1997007833A2 (en) * | 1995-08-29 | 1997-03-06 | Fidia Advanced Biopolymers, S.R.L. | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
US5677276A (en) * | 1994-12-23 | 1997-10-14 | La Jolla Cancer Research Foundation | Immobilization of peptides to hyaluronate |
WO1998008550A1 (en) * | 1996-08-27 | 1998-03-05 | Fusion Medical Technologies, Inc. | Fragmented polymeric hydrogels for adhesion prevention and their preparation |
US5760200A (en) * | 1987-09-18 | 1998-06-02 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US5795584A (en) * | 1993-01-27 | 1998-08-18 | United States Surgical Corporation | Post-surgical anti-adhesion device |
EP0898973A2 (en) * | 1997-08-18 | 1999-03-03 | Medtronic, Inc. | A method of making a crosslinked collagen-based material and bioprosthetic devices produced therefrom |
US5906997A (en) * | 1997-06-17 | 1999-05-25 | Fzio Med, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
US6013679A (en) * | 1989-08-01 | 2000-01-11 | Anika Research, Inc. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
WO2001060868A1 (en) * | 2000-02-14 | 2001-08-23 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6294202B1 (en) | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
US6566345B2 (en) | 2000-04-28 | 2003-05-20 | Fziomed, Inc. | Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
US6610669B1 (en) | 1987-09-18 | 2003-08-26 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US6645947B1 (en) * | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
US6869938B1 (en) | 1997-06-17 | 2005-03-22 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
US6884788B2 (en) | 2001-02-22 | 2005-04-26 | Anika Therapeutics, Inc. | Thiol-modified hyaluronan |
US6903199B2 (en) | 2000-10-10 | 2005-06-07 | Lg Life Sciences Ltd. | Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof |
WO2006036984A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US7192984B2 (en) | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
FR2909285A1 (en) * | 2006-12-01 | 2008-06-06 | Anteis Sa | Use of an injectable or implantable antiadhesive antifibrotic gel based on a crosslinked natural or synthetic polymer for treating glaucoma or surgical wounds |
US7455248B2 (en) | 2004-03-17 | 2008-11-25 | Genzyme Corporation | Powder delivery device |
WO2010051783A1 (en) | 2008-11-06 | 2010-05-14 | Cpn S.R.O. | Method of preparation of dtpa crosslinked hyaluronic acid derivatives and modification of said derivatives |
US7871637B2 (en) | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
WO2011139101A2 (en) * | 2010-05-07 | 2011-11-10 | (주)아모레퍼시픽 | Method for producing the solid phase of a water-insoluble gel composition and a water-insoluble gel produced thereby |
WO2011139103A2 (en) * | 2010-05-07 | 2011-11-10 | (주)아모레퍼시픽 | Method for producing a water-insoluble gel composition and a water-insoluble gel produced thereby |
US8338388B2 (en) | 2003-04-10 | 2012-12-25 | Allergan, Inc. | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8834864B2 (en) | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US8840541B2 (en) | 2010-02-25 | 2014-09-23 | Apollo Endosurgery, Inc. | Pressure sensing gastric banding system |
US8845513B2 (en) | 2002-08-13 | 2014-09-30 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding device |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8876694B2 (en) | 2011-12-07 | 2014-11-04 | Apollo Endosurgery, Inc. | Tube connector with a guiding tip |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8900117B2 (en) | 2004-01-23 | 2014-12-02 | Apollo Endosurgery, Inc. | Releasably-securable one-piece adjustable gastric band |
US8900118B2 (en) | 2008-10-22 | 2014-12-02 | Apollo Endosurgery, Inc. | Dome and screw valves for remotely adjustable gastric banding systems |
US8905915B2 (en) | 2006-01-04 | 2014-12-09 | Apollo Endosurgery, Inc. | Self-regulating gastric band with pressure data processing |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US8940335B2 (en) | 2010-06-01 | 2015-01-27 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US8962025B2 (en) | 2006-08-02 | 2015-02-24 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US8961393B2 (en) | 2010-11-15 | 2015-02-24 | Apollo Endosurgery, Inc. | Gastric band devices and drive systems |
US8961394B2 (en) | 2011-12-20 | 2015-02-24 | Apollo Endosurgery, Inc. | Self-sealing fluid joint for use with a gastric band |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005609B2 (en) | 2003-08-07 | 2015-04-14 | Ethicon, Inc. | Hemostatic compositions containing sterile thrombin |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9028394B2 (en) | 2010-04-29 | 2015-05-12 | Apollo Endosurgery, Inc. | Self-adjusting mechanical gastric band |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
US9044298B2 (en) | 2010-04-29 | 2015-06-02 | Apollo Endosurgery, Inc. | Self-adjusting gastric band |
US9050165B2 (en) | 2010-09-07 | 2015-06-09 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding system |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9162006B2 (en) | 2009-06-16 | 2015-10-20 | Baxter International Inc. | Hemostatic sponge |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US9220820B2 (en) | 2005-10-15 | 2015-12-29 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9295573B2 (en) | 2010-04-29 | 2016-03-29 | Apollo Endosurgery, Inc. | Self-adjusting gastric band having various compliant components and/or a satiety booster |
US9375505B2 (en) | 2010-04-07 | 2016-06-28 | Baxter International Inc. | Hemostatic sponge |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408945B2 (en) | 2010-06-01 | 2016-08-09 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US9517287B2 (en) | 2009-12-16 | 2016-12-13 | Baxter International, Inc. | Hemostatic sponge |
US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
CN106573089A (en) * | 2014-05-16 | 2017-04-19 | 奥创斯特公司 | Phase-shifting formulations |
US9682175B2 (en) | 2004-09-28 | 2017-06-20 | Atrium Medical Corporation | Coating material and medical device system including same |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9821025B2 (en) | 2011-10-11 | 2017-11-21 | Baxter International Inc. | Hemostatic compositions |
US9833541B2 (en) | 2011-10-27 | 2017-12-05 | Baxter International Inc. | Hemostatic compositions |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US10322170B2 (en) | 2011-10-11 | 2019-06-18 | Baxter International Inc. | Hemostatic compositions |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11020421B2 (en) | 2017-04-05 | 2021-06-01 | Gelesis Llc | Superabsorbent materials and methods of production thereof |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US11980699B2 (en) | 2021-09-01 | 2024-05-14 | Shanghai Qisheng Biological Preparation Co., Ltd. | Cartilage regeneration using injectable, in situ polymerizable collagen compositions containing chondrocytes or stem cells |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080893A (en) * | 1988-05-31 | 1992-01-14 | University Of Florida | Method for preventing surgical adhesions using a dilute solution of polymer |
US6235726B1 (en) * | 1987-09-18 | 2001-05-22 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US5140016A (en) * | 1988-05-31 | 1992-08-18 | University Of Florida | Method and composition for preventing surgical adhesions using a dilute solution of polymer |
US6010692A (en) * | 1988-05-31 | 2000-01-04 | University Of Florida Research Foundation, Inc. | Method and composition for preventing surgical adhesions and tissue damage |
SE8900586L (en) * | 1989-02-21 | 1990-08-22 | Pharmacia Ab | COMPOSITION AND PROCEDURES TO PREVENT ADHESION BETWEEN BODY TISSUE |
US5059123A (en) * | 1990-05-14 | 1991-10-22 | Jernberg Gary R | Periodontal barrier and method for aiding periodontal tissue regeneration |
US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5143724A (en) * | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
US5705178A (en) * | 1991-05-31 | 1998-01-06 | Gliatech, Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
JP2855307B2 (en) * | 1992-02-05 | 1999-02-10 | 生化学工業株式会社 | Photoreactive glycosaminoglycans, cross-linked glycosaminoglycans and methods for producing them |
US5690961A (en) * | 1994-12-22 | 1997-11-25 | Hercules Incorporated | Acidic polysaccharides crosslinked with polycarboxylic acids and their uses |
US5888988A (en) * | 1995-05-08 | 1999-03-30 | Chitogenics, Inc. | Covalently linked N,O-carboxymethylchitosan and uses thereof |
US5679658A (en) * | 1995-05-08 | 1997-10-21 | Chitogenics, Inc. | N,O-carbonxymethylchitosan for prevention of surgical adhesions |
US5807833A (en) * | 1995-06-07 | 1998-09-15 | University Of Southern California | Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device |
EP0830381A4 (en) * | 1995-06-09 | 2000-11-22 | William N Drohan | Chitin hydrogels, methods of their production and use |
US5612321A (en) * | 1995-06-22 | 1997-03-18 | Hercules Incorporated | Antioxidant grafted polysaccharides |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US20050090662A1 (en) * | 1997-01-15 | 2005-04-28 | Beavers Ellington M. | Method of making free acids from polysaccharide salts |
US6123957A (en) * | 1997-07-16 | 2000-09-26 | Jernberg; Gary R. | Delivery of agents and method for regeneration of periodontal tissues |
US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
US6514534B1 (en) * | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
GB9826658D0 (en) * | 1998-12-03 | 1999-01-27 | Univ London | Tissue repair |
US7083777B1 (en) | 1999-04-02 | 2006-08-01 | The Brigham And Women's Hospital, Inc. | Immunomodulating polymers |
CA2377544C (en) * | 1999-07-28 | 2008-09-23 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
AU2002236587A1 (en) | 2000-11-21 | 2002-06-03 | Michael P. Diamond | Compositions for adhesion prevention |
SV2003000753A (en) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
US7265097B2 (en) * | 2002-08-20 | 2007-09-04 | Chitogenics, Inc. | Methods of drug delivery using sulphated chitinous polymers |
AU2003262871B2 (en) | 2002-08-28 | 2008-02-28 | Apollo Endosurgery, Inc. | Fatigue-resistant gastric banding device |
EP1638581A2 (en) * | 2003-03-31 | 2006-03-29 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
MXPA06010204A (en) | 2004-03-08 | 2007-03-07 | Endoart Sa | Closure system for tubular organs. |
CA2569043C (en) | 2004-03-18 | 2010-08-17 | Allergan, Inc. | Apparatus and method for volume adjustment of intragastric balloons |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US8251888B2 (en) | 2005-04-13 | 2012-08-28 | Mitchell Steven Roslin | Artificial gastric valve |
US7798954B2 (en) | 2006-01-04 | 2010-09-21 | Allergan, Inc. | Hydraulic gastric band with collapsible reservoir |
WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
JP2009533455A (en) * | 2006-04-12 | 2009-09-17 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions and methods for inhibiting adhesions |
WO2008147867A2 (en) | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US20110077737A1 (en) * | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US20090062233A1 (en) | 2007-08-09 | 2009-03-05 | Xin Ji | Modified starch material of biocompatible hemostasis |
US8697044B2 (en) * | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
CN104888263B (en) | 2008-01-14 | 2018-11-30 | 北京环球利康科技有限公司 | Biocompatible hemostatic prevents adhesion, promoting healing, the closed modified starch material of surgery |
EP2095832A1 (en) | 2008-02-28 | 2009-09-02 | Bayer MaterialScience AG | Post-operative adhesion barriers |
US8932622B2 (en) * | 2008-06-03 | 2015-01-13 | Actamax Surgical Materials, Llc | Tissue coating for preventing undesired tissue-to-tissue adhesions |
US20100305397A1 (en) * | 2008-10-06 | 2010-12-02 | Allergan Medical Sarl | Hydraulic-mechanical gastric band |
US8317677B2 (en) | 2008-10-06 | 2012-11-27 | Allergan, Inc. | Mechanical gastric band with cushions |
WO2010101931A2 (en) | 2009-03-03 | 2010-09-10 | Access Medical System Co., Ltd. | Detection system and method for high sensitivity fluorescent assays |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8758221B2 (en) | 2010-02-24 | 2014-06-24 | Apollo Endosurgery, Inc. | Source reservoir with potential energy for remotely adjustable gastric banding system |
US8517915B2 (en) | 2010-06-10 | 2013-08-27 | Allergan, Inc. | Remotely adjustable gastric banding system |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9999500B2 (en) | 2011-03-10 | 2018-06-19 | University Of Florida Research Foundation, Inc. | Anti thrombogenic heart valve and medical implements |
EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
EP2612846A1 (en) | 2012-01-09 | 2013-07-10 | Bayer MaterialScience AG | Beta amino acid esters and use of same |
KR101240518B1 (en) | 2012-03-26 | 2013-03-11 | 주식회사 제네웰 | Raw materials for transplantation using biocompatible polymers |
US9623157B2 (en) | 2013-03-15 | 2017-04-18 | Lake Region Manufacturing, Inc. | Modified hyaluronate hydrophilic compositions, coatings and methods |
US20140275340A1 (en) | 2013-03-15 | 2014-09-18 | Lake Region Manufacturing, Inc. d/b/a Lake Region Medical | Modified hyaluronate hydrophilic compositions, coatings and methods |
ES2653549T3 (en) * | 2013-09-30 | 2018-02-07 | Galderma S.A. | Functionalization and cross-linking of hyaluronic acid in one step |
JP6918365B2 (en) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Lipidized PSA Compositions and Methods |
CA3030974A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
RU2750000C1 (en) * | 2019-12-25 | 2021-06-21 | Акционерное общество «Медтехнопроект» | Method for synthesis of modified hyaluronan and application thereof in medicine, including in endoprosthetics |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3042667A (en) * | 1959-03-10 | 1962-07-03 | Pharmacia Ab | Process for producing dextran derivatives and products resulting therefrom |
DE2631908A1 (en) * | 1975-07-15 | 1977-02-10 | Massachusetts Inst Technology | NETWORKED POLYMER |
US4470975A (en) * | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE169293C1 (en) * | 1958-03-13 | 1959-11-10 | ||
NL126243C (en) * | 1959-06-12 | |||
SE319903B (en) * | 1964-01-31 | 1970-01-26 | Pharmacia Ab | |
SE452109B (en) * | 1973-01-29 | 1987-11-16 | Pharmacia Ab | SCIENTIFIC CLEANER EXTENDED SARYTOR |
US4002173A (en) * | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
US4152170A (en) * | 1975-06-18 | 1979-05-01 | Sumitomo Chemical Company, Ltd. | Cross-linked pullulan |
US4011392A (en) * | 1975-09-02 | 1977-03-08 | The Sherwin-Williams Company | Mixed starch esters and the use thereof |
DE2707308C2 (en) * | 1977-02-19 | 1982-07-01 | Hoechst Ag, 6000 Frankfurt | Shaped bodies with a spongy structure based on regenerated cellulose for medical purposes |
JPS5844084B2 (en) * | 1977-04-01 | 1983-09-30 | 住友化学工業株式会社 | Manufacturing method of ionic pullulan gel |
FI793150A (en) * | 1978-10-12 | 1980-04-13 | Battelle Memorial Institute | FOERFARANDE FOER TVAERBINDNING AV KARBOXYMETYLCELLULOSA OCH ERHAOLLNA PRODUKTER |
JPS60130601A (en) * | 1983-12-15 | 1985-07-12 | バイオマトリツクス,インコ−ポレイテツド | Manufacture of hyaluronic acid water-insoluble composition |
US4605691A (en) * | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
-
1984
- 1984-07-23 SE SE8403817A patent/SE456346B/en not_active IP Right Cessation
-
1985
- 1985-07-05 CA CA000486349A patent/CA1263647A/en not_active Expired
- 1985-07-16 US US06/847,171 patent/US4886787A/en not_active Expired - Lifetime
- 1985-07-16 EP EP85903721A patent/EP0190215B1/en not_active Expired
- 1985-07-16 WO PCT/SE1985/000282 patent/WO1986000912A1/en active IP Right Grant
- 1985-07-16 JP JP60503288A patent/JPH0669490B2/en not_active Expired - Lifetime
- 1985-07-16 DE DE8585903721T patent/DE3573785D1/en not_active Expired
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3042667A (en) * | 1959-03-10 | 1962-07-03 | Pharmacia Ab | Process for producing dextran derivatives and products resulting therefrom |
DE2631908A1 (en) * | 1975-07-15 | 1977-02-10 | Massachusetts Inst Technology | NETWORKED POLYMER |
US4470975A (en) * | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
Non-Patent Citations (1)
Title |
---|
Chemical Abstract Vol. 87 (1977) abstract no. 73342 * |
Cited By (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007898A1 (en) * | 1986-06-18 | 1987-12-30 | Pharmacia Ab | Material of polysaccharides containing carboxyl groups, and a process for producing such polysaccharides |
WO1989002445A1 (en) * | 1987-09-18 | 1989-03-23 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US4937270A (en) * | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US5760200A (en) * | 1987-09-18 | 1998-06-02 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US5527893A (en) * | 1987-09-18 | 1996-06-18 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US6610669B1 (en) | 1987-09-18 | 2003-08-26 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US6174999B1 (en) | 1987-09-18 | 2001-01-16 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
US6943154B2 (en) | 1987-09-18 | 2005-09-13 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
EP0345370A1 (en) * | 1988-06-08 | 1989-12-13 | Malliner Laboratories Inc. | Use of transparent membranes made of hydrogel polymers as a cover for various organs during surgery |
US6096727A (en) * | 1989-08-01 | 2000-08-01 | Anika Therapeutics, Inc. | Method for treating wounds using modified hyaluronic acid crosslinked with biscarbodiimide |
US6013679A (en) * | 1989-08-01 | 2000-01-11 | Anika Research, Inc. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US6537979B1 (en) | 1989-08-01 | 2003-03-25 | Research Foundation Of State University Of New York | Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide |
US4994277A (en) * | 1989-10-31 | 1991-02-19 | Pfizer Hospital Products Group, Inc. | Use of xanthan gum for preventing adhesions |
EP0426368A3 (en) * | 1989-10-31 | 1992-04-01 | Pfizer Hospital Products Group, Inc. | Compositions containing derivatives of chitin for preventing adhesion |
US5093319A (en) * | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
EP0426368A2 (en) * | 1989-10-31 | 1991-05-08 | Howmedica Inc. | Compositions containing derivatives of chitin for preventing adhesion |
US5017229A (en) * | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
EP1593394A3 (en) * | 1991-04-05 | 2007-08-01 | Lifecore Biomedical, Inc. | Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention |
GR920100122A (en) * | 1991-04-05 | 1993-03-16 | Ethicon Inc | Ionically crosslinked carboxyl-containing polysaccharides for adhension prevention. |
EP0507604A2 (en) * | 1991-04-05 | 1992-10-07 | Lifecore Biomedical, Inc. | Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention |
EP1593394A2 (en) * | 1991-04-05 | 2005-11-09 | Lifecore Biomedical, Inc. | Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention |
EP0507604A3 (en) * | 1991-04-05 | 1993-10-06 | Ethicon Inc. | Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention |
US5532221A (en) * | 1991-04-05 | 1996-07-02 | Lifecore Biomedical, Inc. | Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention |
EP0610441A4 (en) * | 1991-10-29 | 1996-01-10 | Clover Cons Ltd | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release. |
DE4209160A1 (en) * | 1992-03-20 | 1993-09-30 | Bauer Kurt Heinz Prof Dr | Crosslinked polysaccharides, process for their preparation and their use |
US5795584A (en) * | 1993-01-27 | 1998-08-18 | United States Surgical Corporation | Post-surgical anti-adhesion device |
EP0686395A2 (en) | 1994-06-07 | 1995-12-13 | Genzyme Corporation | Use of hyaluronic acid for the manufacture of a medicament for the inhibition of platelet aggregation |
US6703041B2 (en) | 1994-10-06 | 2004-03-09 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
US6294202B1 (en) | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
US5677276A (en) * | 1994-12-23 | 1997-10-14 | La Jolla Cancer Research Foundation | Immobilization of peptides to hyaluronate |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
US7504386B2 (en) | 1995-08-29 | 2009-03-17 | Fidia Advanced Biopolymers, S.R.L | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
WO1997007833A3 (en) * | 1995-08-29 | 1997-04-10 | Fidia Advanced Biopolymers Srl | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
US6723709B1 (en) | 1995-08-29 | 2004-04-20 | Fidia Advanced Biopolymers, S.R.L. | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
WO1997007833A2 (en) * | 1995-08-29 | 1997-03-06 | Fidia Advanced Biopolymers, S.R.L. | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
US7871637B2 (en) | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
WO1998008550A1 (en) * | 1996-08-27 | 1998-03-05 | Fusion Medical Technologies, Inc. | Fragmented polymeric hydrogels for adhesion prevention and their preparation |
US6133325A (en) * | 1997-06-17 | 2000-10-17 | Fziomed, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
US6017301A (en) * | 1997-06-17 | 2000-01-25 | Fziomed, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
US6034140A (en) * | 1997-06-17 | 2000-03-07 | Fziomed, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
US7192984B2 (en) | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US5906997A (en) * | 1997-06-17 | 1999-05-25 | Fzio Med, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
US6869938B1 (en) | 1997-06-17 | 2005-03-22 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
EP0898973A2 (en) * | 1997-08-18 | 1999-03-03 | Medtronic, Inc. | A method of making a crosslinked collagen-based material and bioprosthetic devices produced therefrom |
EP0898973A3 (en) * | 1997-08-18 | 2000-09-27 | Medtronic, Inc. | A method of making a crosslinked collagen-based material and bioprosthetic devices produced therefrom |
US6809085B1 (en) * | 1999-05-20 | 2004-10-26 | Chitogenics, Inc. | Adherent N,O-Carboxymethylchitosan drug delivery devices for moist tissue and methods of their use |
US6894035B2 (en) * | 1999-05-20 | 2005-05-17 | Chitogenics, Inc. | Adhesive N,O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
US7238678B2 (en) * | 1999-05-20 | 2007-07-03 | Chitogenics, Inc. | Adhesive N,O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
US6645947B1 (en) * | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
US7265098B2 (en) | 1999-12-27 | 2007-09-04 | Fziomed, Inc. | Polyacid/polyalkylene oxide gels and methods for their delivery |
WO2001060868A1 (en) * | 2000-02-14 | 2001-08-23 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6521223B1 (en) | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6566345B2 (en) | 2000-04-28 | 2003-05-20 | Fziomed, Inc. | Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
US6903199B2 (en) | 2000-10-10 | 2005-06-07 | Lg Life Sciences Ltd. | Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof |
US6884788B2 (en) | 2001-02-22 | 2005-04-26 | Anika Therapeutics, Inc. | Thiol-modified hyaluronan |
US8845513B2 (en) | 2002-08-13 | 2014-09-30 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding device |
US10080767B2 (en) | 2003-04-10 | 2018-09-25 | Allergan Industrie Sas | Injectable monophase hydrogels |
US10653716B2 (en) | 2003-04-10 | 2020-05-19 | Allergan Industrie, Sas | Injectable monophase hydrogels |
US11045490B2 (en) | 2003-04-10 | 2021-06-29 | Allergan Industrie, Sas | Injectable monophase hydrogels |
US8338388B2 (en) | 2003-04-10 | 2012-12-25 | Allergan, Inc. | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US9062130B2 (en) | 2003-04-10 | 2015-06-23 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US8834864B2 (en) | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US9005609B2 (en) | 2003-08-07 | 2015-04-14 | Ethicon, Inc. | Hemostatic compositions containing sterile thrombin |
US8900117B2 (en) | 2004-01-23 | 2014-12-02 | Apollo Endosurgery, Inc. | Releasably-securable one-piece adjustable gastric band |
US7455248B2 (en) | 2004-03-17 | 2008-11-25 | Genzyme Corporation | Powder delivery device |
US10016465B2 (en) | 2004-09-28 | 2018-07-10 | Atrium Medical Corporation | Cured gel and method of making |
WO2006036984A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
EP1812022A2 (en) * | 2004-09-28 | 2007-08-01 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US10772995B2 (en) | 2004-09-28 | 2020-09-15 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10792312B2 (en) | 2004-09-28 | 2020-10-06 | Atrium Medical Corporation | Barrier layer |
US10814043B2 (en) | 2004-09-28 | 2020-10-27 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8858978B2 (en) | 2004-09-28 | 2014-10-14 | Atrium Medical Corporation | Heat cured gel and method of making |
US11793912B2 (en) | 2004-09-28 | 2023-10-24 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10869902B2 (en) | 2004-09-28 | 2020-12-22 | Atrium Medical Corporation | Cured gel and method of making |
US9827352B2 (en) | 2004-09-28 | 2017-11-28 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US8962023B2 (en) | 2004-09-28 | 2015-02-24 | Atrium Medical Corporation | UV cured gel and method of making |
EP1812022A4 (en) * | 2004-09-28 | 2011-08-31 | Atrium Medical Corp | Stand-alone film and methods for making the same |
US9682175B2 (en) | 2004-09-28 | 2017-06-20 | Atrium Medical Corporation | Coating material and medical device system including same |
US11083823B2 (en) | 2005-09-28 | 2021-08-10 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9220820B2 (en) | 2005-10-15 | 2015-12-29 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US8905915B2 (en) | 2006-01-04 | 2014-12-09 | Apollo Endosurgery, Inc. | Self-regulating gastric band with pressure data processing |
US8962025B2 (en) | 2006-08-02 | 2015-02-24 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US9114172B2 (en) | 2006-08-02 | 2015-08-25 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
FR2909285A1 (en) * | 2006-12-01 | 2008-06-06 | Anteis Sa | Use of an injectable or implantable antiadhesive antifibrotic gel based on a crosslinked natural or synthetic polymer for treating glaucoma or surgical wounds |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US9238013B2 (en) | 2008-08-04 | 2016-01-19 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US10328180B2 (en) | 2008-08-04 | 2019-06-25 | Allergan Industrie, S.A.S. | Hyaluronic acid-based gels including lidocaine |
US9358322B2 (en) | 2008-08-04 | 2016-06-07 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089519B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089518B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10391202B2 (en) | 2008-08-04 | 2019-08-27 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10485896B2 (en) | 2008-08-04 | 2019-11-26 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US8900118B2 (en) | 2008-10-22 | 2014-12-02 | Apollo Endosurgery, Inc. | Dome and screw valves for remotely adjustable gastric banding systems |
WO2010051783A1 (en) | 2008-11-06 | 2010-05-14 | Cpn S.R.O. | Method of preparation of dtpa crosslinked hyaluronic acid derivatives and modification of said derivatives |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US11166929B2 (en) | 2009-03-10 | 2021-11-09 | Atrium Medical Corporation | Fatty-acid based particles |
US10285964B2 (en) | 2009-03-10 | 2019-05-14 | Atrium Medical Corporation | Fatty-acid based particles |
US9993298B2 (en) | 2009-05-18 | 2018-06-12 | Baxter International Inc. | Method for the improvement of mesh implant biocompatibility |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
US9162006B2 (en) | 2009-06-16 | 2015-10-20 | Baxter International Inc. | Hemostatic sponge |
US9517287B2 (en) | 2009-12-16 | 2016-12-13 | Baxter International, Inc. | Hemostatic sponge |
US9855367B2 (en) | 2010-01-13 | 2018-01-02 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10449268B2 (en) | 2010-01-13 | 2019-10-22 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US10220113B2 (en) | 2010-01-13 | 2019-03-05 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US9655991B2 (en) | 2010-01-13 | 2017-05-23 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US8840541B2 (en) | 2010-02-25 | 2014-09-23 | Apollo Endosurgery, Inc. | Pressure sensing gastric banding system |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US9125840B2 (en) | 2010-03-12 | 2015-09-08 | Allergan Industrie Sas | Methods for improving skin conditions |
US9585821B2 (en) | 2010-03-12 | 2017-03-07 | Allergan Industrie Sas | Methods for making compositions for improving skin conditions |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9012517B2 (en) | 2010-03-22 | 2015-04-21 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9480775B2 (en) | 2010-03-22 | 2016-11-01 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10441674B2 (en) | 2010-04-07 | 2019-10-15 | Baxter International Inc. | Hemostatic sponge |
US9375505B2 (en) | 2010-04-07 | 2016-06-28 | Baxter International Inc. | Hemostatic sponge |
US11478566B2 (en) | 2010-04-07 | 2022-10-25 | Baxter International Inc. | Hemostatic sponge |
US9044298B2 (en) | 2010-04-29 | 2015-06-02 | Apollo Endosurgery, Inc. | Self-adjusting gastric band |
US9028394B2 (en) | 2010-04-29 | 2015-05-12 | Apollo Endosurgery, Inc. | Self-adjusting mechanical gastric band |
US9295573B2 (en) | 2010-04-29 | 2016-03-29 | Apollo Endosurgery, Inc. | Self-adjusting gastric band having various compliant components and/or a satiety booster |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
WO2011139101A3 (en) * | 2010-05-07 | 2012-03-22 | (주)아모레퍼시픽 | Method for producing the solid phase of a water-insoluble gel composition and a water-insoluble gel produced thereby |
WO2011139101A2 (en) * | 2010-05-07 | 2011-11-10 | (주)아모레퍼시픽 | Method for producing the solid phase of a water-insoluble gel composition and a water-insoluble gel produced thereby |
WO2011139103A2 (en) * | 2010-05-07 | 2011-11-10 | (주)아모레퍼시픽 | Method for producing a water-insoluble gel composition and a water-insoluble gel produced thereby |
WO2011139103A3 (en) * | 2010-05-07 | 2012-03-08 | (주)아모레퍼시픽 | Method for producing a water-insoluble gel composition and a water-insoluble gel produced thereby |
US8940335B2 (en) | 2010-06-01 | 2015-01-27 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9408945B2 (en) | 2010-06-01 | 2016-08-09 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US10994045B2 (en) | 2010-06-01 | 2021-05-04 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US10245348B2 (en) | 2010-06-01 | 2019-04-02 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US11097035B2 (en) | 2010-07-16 | 2021-08-24 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US9050165B2 (en) | 2010-09-07 | 2015-06-09 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding system |
US8961393B2 (en) | 2010-11-15 | 2015-02-24 | Apollo Endosurgery, Inc. | Gastric band devices and drive systems |
US9737633B2 (en) | 2011-06-03 | 2017-08-22 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US9950092B2 (en) | 2011-06-03 | 2018-04-24 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9962464B2 (en) | 2011-06-03 | 2018-05-08 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US10434214B2 (en) | 2011-09-06 | 2019-10-08 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10322170B2 (en) | 2011-10-11 | 2019-06-18 | Baxter International Inc. | Hemostatic compositions |
US9821025B2 (en) | 2011-10-11 | 2017-11-21 | Baxter International Inc. | Hemostatic compositions |
US9833541B2 (en) | 2011-10-27 | 2017-12-05 | Baxter International Inc. | Hemostatic compositions |
US8876694B2 (en) | 2011-12-07 | 2014-11-04 | Apollo Endosurgery, Inc. | Tube connector with a guiding tip |
US8961394B2 (en) | 2011-12-20 | 2015-02-24 | Apollo Endosurgery, Inc. | Self-sealing fluid joint for use with a gastric band |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10888617B2 (en) | 2012-06-13 | 2021-01-12 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
AU2015258997B2 (en) * | 2014-05-16 | 2019-04-18 | Ultrast, Inc. | Phase-shifting formulations |
CN106573089A (en) * | 2014-05-16 | 2017-04-19 | 奥创斯特公司 | Phase-shifting formulations |
EP3142718A4 (en) * | 2014-05-16 | 2017-11-29 | Ultrast, Inc. | Phase-shifting formulations |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11020421B2 (en) | 2017-04-05 | 2021-06-01 | Gelesis Llc | Superabsorbent materials and methods of production thereof |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
US11980699B2 (en) | 2021-09-01 | 2024-05-14 | Shanghai Qisheng Biological Preparation Co., Ltd. | Cartilage regeneration using injectable, in situ polymerizable collagen compositions containing chondrocytes or stem cells |
Also Published As
Publication number | Publication date |
---|---|
EP0190215B1 (en) | 1989-10-18 |
CA1263647A (en) | 1989-12-05 |
SE456346B (en) | 1988-09-26 |
DE3573785D1 (en) | 1989-11-23 |
JPS61502729A (en) | 1986-11-27 |
SE8403817D0 (en) | 1984-07-23 |
EP0190215A1 (en) | 1986-08-13 |
JPH0669490B2 (en) | 1994-09-07 |
SE8403817L (en) | 1986-01-24 |
US4886787A (en) | 1989-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4886787A (en) | Method of preventing adhesion between body tissues, means for preventing such adhesion, and process for producing said means | |
US5093319A (en) | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions | |
KR100730527B1 (en) | Hyaluronic acid gel composition, process for producing the same, and medical material containing the same | |
US6391939B2 (en) | Collagenic material useful in particular for preventing post-operative adhesions | |
US7226972B2 (en) | Process for cross-linking hyaluronic acid to polymers | |
US4716154A (en) | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute | |
DK1149116T5 (en) | Process for the preparation of multiple crosslinked hyaluronic acid derivatives | |
WO1993013136A1 (en) | Ultra-pure polysaccharide materials for medical use | |
EP0426368B1 (en) | Compositions containing derivatives of chitin for preventing adhesion | |
JP2012082428A (en) | Composition of semi-interpenetrating polymer network | |
RU1824197C (en) | Method for preparing radiopaque composition | |
JP3420851B2 (en) | Anti-adhesion agent | |
KR102103180B1 (en) | Anti-adhesion Composition Including Hyaluronic Acid Derivative, Pullulan and Carboxymethyl Cellulose and Manufacturing Method Thereof | |
CN114099787B (en) | Absorbable biological membrane, preparation method and application thereof | |
CN115845144A (en) | Preparation method of chitosan-bioactive glass composite bone rod and bone plate | |
Collins et al. | Hydrogel functionalization and crosslinking strategies for biomedical applications | |
JPH0826081B2 (en) | Method for insolubilizing N-carboxyalkyl derivative of chitosan | |
US5821285A (en) | Method of preparing filler containing forms of chitin | |
JPH03165775A (en) | Medical material constituted of succinyl chitosan | |
JPH0360272B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1985903721 Country of ref document: EP |
|
AK | Designated states |
Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1985903721 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1985903721 Country of ref document: EP |